Article Sidebar
Views PDF: 113
NGHIÊN CỨU SỰ BỘC LỘ DẤU ẤN PD-L1 Ở BỆNH NHÂN UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ
Main Article Content
Abstract
Objective: to investigate the prevalence of PD-L1 expression and its correlation with histopathological subtypes and EGFR gene mutation characteristics in patients with non-small cell lung cancer (NSCLC). Subjects and methods: a cross-sectional study conducted on 138 patients diagnosed with NSCLC at 103 Military Hospital from June 2021 to June 2023. Histopathological subtypes, EGFR gene mutation, and the PD-L1 expression were determined based on the patient's biopsy samples. Prevalence of PD-L1 expression and its correlation with the collected factors were archived. Results: 48.5% of cases were positive for PD-L1, including 18,8% cases with tumor proportion score (TPS) ranging from 1% to 49% and 29.7% cases with TPS≥50. The expression of PD-L1 had no correlation with age, gender, and histopathological subtypes but was significantly associated with EGFR status: tumor cells with PD-L1 positive had a low rate of EGFR gene mutations. Conclusion: PD-L1 expression had a significant correlation with wild-type EGFR
Article Details
Keywords
PD-L1, Non-small cell lung cancer (NSCLC), EGFR mutation
References
2. Ettinger David S, Wood Douglas E, Aisner Dara L, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. Journal of the national comprehensive cancer network. 2017; 15(4):504-535.
3. Rittmeyer Achim, Barlesi Fabrice, Waterkamp Daniel, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. The Lancet. 2017; 389(10066):255-265.
4. Pawelczyk Konrad, Piotrowska Aleksandra, Ciesielska Urszula, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. International journal of molecular sciences. 2019; 20(4):824.
5. D’Arcangelo Manolo, D’Incecco Armida, Ligorio Claudia, et al. Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. Oncotarget. 2019; 10(5):561.
6. Barlesi Fabrice, Vansteenkiste Johan, Spigel David, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): An open-label, randomised, phase 3 study. The Lancet Oncology. 2018; 19(11):1468-1479.
7. Pan Zhen-Kui, Ye Feng, Wu Xuan, et al. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: A meta-analysis. Journal of thoracic disease. 2015; 7(3):462.
8. Zhang Minghui, Li Guoliang, Wang Yanbo, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: A meta-analysis. Scientific reports. 2017; 7(1):10255.
9. Rangachari Deepa, VanderLaan Paul A, Shea Meghan, et al. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥ 50% expression in lung adenocarcinoma. Journal of thoracic oncology. 2017; 12(5):878-883.
10. Gainor Justin F, Shaw Alice T, Sequist Lecia V, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clinical cancer research. 2016; 22(18): 4585-4593.